(Q52940970)

9 May 2018

title

Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. (English)

1 reference

9 May 2018

childhood acute myeloid leukemia

main subject

1 reference

Claudia Langebrake

1

1 reference

9 May 2018

Iris Brinkmann

2

1 reference

9 May 2018

Andrea Teigler-Schlegel

3

1 reference

9 May 2018

Ursula Creutzig

4

1 reference

9 May 2018

Frank Griesinger

5

1 reference

9 May 2018

Ulrike Puhlmann

6

1 reference

9 May 2018

Dirk Reinhardt

7

1 reference

9 May 2018

publication date

1 January 2005

1 reference

9 May 2018

Cytometry Part B: Clinical Cytometry

published in

1 reference

9 May 2018

volume

63

1 reference

9 May 2018

issue

1

1 reference

9 May 2018

page(s)

1-9

1 reference

9 May 2018

Characterization of aberrant phenotypes in acute myeloblastic leukemia

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Molecular diagnosis and monitoring of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Detection of minimal residual disease in acute leukemia by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Immunophenotypic and cytogenetic changes in acute leukaemia at relapse

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Antigen expression patterns reflecting genotype of acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Surface marker expression in acute myeloid leukaemia at first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20037

7 January 2021

Identifiers

DOI

10.1002/CYTO.B.20037

1 reference

9 May 2018

PubMed ID

15624201

1 reference

9 May 2018